Related Experiment Video
Updated: Feb 2, 2026

Monitoring Influenza Virus Survival Outside the Host Using Real-Time Cell Analysis
Published on: February 20, 2021
Pirfenidone improves survival in IPF: results from a real-life study
George A Margaritopoulos1,2, Athina Trachalaki1, Athol U Wells2
1Respiratory Medicine Department, University Hospital of Heraklion, Crete, Greece.
Background:
Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone's effect on mortality and adverse events profile outside the restrictions of a clinical trial.
Methods:
This is a retrospective observational intention to treat study of 82 consecutive IPF patients (UHH cohort).
Results:
We observed a high 3-years survival rate of 73% without excluding patients who discontinued treatment for different reasons. The survival was compared to the survival of an IPF cohort from a tertiary referral center (RBH cohort). After exclusion of severe cases (DLco< 30%), in unadjusted analysis, the survival in the UHH cohort was better than in the RBH cohort (HR:0.32, 95% CI: 0.19-0.53, p < 0.0001). After adjustment for age, gender and FVC, the survival remained higher in the UHH cohort (HR:0.28, 95% CI: 0.16-0.48, p < 0.0001). We observed a similar safety profile compared to previously published data and a lower rate of drug discontinuation due to photosensitivity reactions.
Conclusion:
Pirfenidone provides a survival benefit in a real-life IPF cohort compared to previously used medications. Counselling patients and proactively managing possible adverse effects can reduce the necessity to discontinue pirfenidone.
Insights
Pirfenidone treatment improved survival in idiopathic pulmonary fibrosis (IPF) patients in a real-world setting. Proactive management of side effects reduced treatment discontinuation, enhancing pirfenidone
Area of Science:
- Pulmonology
- Pharmacology
- Real-world evidence studies
Background:
- Pirfenidone is an approved antifibrotic medication for idiopathic pulmonary fibrosis (IPF).
- Real-world data on pirfenidone's impact on mortality and adverse events is crucial outside clinical trial settings.
Purpose of the Study:
- To evaluate the real-world effect of pirfenidone on mortality in IPF patients.
- To assess the adverse events profile of pirfenidone in a clinical practice setting.
- To compare survival rates between IPF patients treated with pirfenidone and a historical cohort.
Main Methods:
- Retrospective observational intention-to-treat study.
- Involved 82 consecutive IPF patients (UHH cohort).
- Compared survival data with an IPF cohort from a tertiary referral center (RBH cohort).
Main Results:
- A 3-year survival rate of 73% was observed in the UHH cohort, including patients who discontinued treatment.
- Pirfenidone treatment was associated with significantly better survival compared to the RBH cohort, even after adjusting for age, gender, and FVC (HR:0.28, 95% CI: 0.16-0.48).
- A similar safety profile to previous studies was noted, with a lower rate of discontinuation due to photosensitivity.
Conclusions:
- Pirfenidone demonstrates a survival benefit in a real-world IPF patient cohort.
- Effective patient counseling and proactive management of adverse effects can minimize pirfenidone discontinuation.
Related Concept Videos
The Angiosperm Life Cycle
Half-life of a Reaction
Characteristics of Life
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...
The Tree of Life - Bacteria, Archaea, Eukaryotes

